SLC5A2 and type 2 diabetes mellitus: In a double-blind, placebo-controlled clinical trial, patients with diabetes type 2 and NAFLD receiving only dapagliflozin had decreased both CK18-M65 and CK18-M30, which suggests a protective effect of SGLT2 inhibitors on hepatocytes in T2DM patients (Table 1) [57].